Edesa Biotech (EDSA) Non-Current Assets (2013 - 2026)
Edesa Biotech (EDSA) posted Non-Current Assets of $2.0 million for Q4 2025, down 1.22% sequentially from $2.0 million in Q3 2025, and down 4.75% YoY from $2.1 million in Q4 2024.
Edesa Biotech (EDSA) Non-Current Assets (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Non-Current Assets for 13 years, with the latest figure at $2.0 million in Q4 2025.
- Quarterly Non-Current Assets fell 4.75% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.1 million (down 6.05% YoY) and the FY2025 annual result came in at $2.0 million, down 5.65% from the prior year.
- Non-Current Assets declined to $2.0 million in Q4 2025 per EDSA's latest filing, from $2.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $2.6 million in Q4 2022 and troughed at $2.0 million in Q4 2025.
- A 5-year average of $2.3 million and a median of $2.4 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2024: Non-Current Assets jumped 1150.39% in 2021, then slipped 13.38% in 2024.
- Over 5 years, Non-Current Assets stood at $2.5 million in 2021, then gained by 5.57% to $2.6 million in 2022, then dropped by 6.67% to $2.4 million in 2023, then retreated by 13.38% to $2.1 million in 2024, then fell by 4.75% to $2.0 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $2.0 million, $2.0 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 18.06 Bn |
| 10 | Edesa Biotech | 42.25 Mn | 42.25 Mn | - | 1.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.94 Mn |
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 2.04 Mn |
| Mar 31, 2025 | 2.07 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.14 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Mar 31, 2024 | 2.23 Mn |
| Dec 31, 2023 | 2.42 Mn |
| Sep 30, 2023 | 2.45 Mn |
| Jun 30, 2023 | 2.51 Mn |
| Mar 31, 2023 | 2.54 Mn |
| Dec 31, 2022 | 2.59 Mn |
| Sep 30, 2022 | 2.48 Mn |
| Jun 30, 2022 | 2.36 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 2.45 Mn |
| Sep 30, 2021 | 2.49 Mn |
| Jun 30, 2021 | 2.54 Mn |